Vitrakvi

Active Ingredient(s): Larotrectinib
FDA Approved: * November 26, 2018
Pharm Company: * LOXO ONCOLOGY INC
Category: Cancer

Larotrectinib, sold under the brand name Vitrakvi, is a medication for the treatment of cancer.[1][2][3] It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC.[4][5][6] It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013. Larotrectinib was initially awarded orphan drug status in 2015, for soft tissue sarcoma, and breakthrough therapy designation in 2016 for ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Vitrakvi 25 mg Oral Capsule
NDC: 50419-390
Labeler:
Bayer Healthcare Pharmaceuticals Inc.
Vitrakvi 100 mg Oral Capsule
NDC: 50419-391
Labeler:
Bayer Healthcare Pharmaceuticals Inc.
Vitrakvi 20 mg/ml Oropharyngeal Solution, Concentrate
NDC: 50419-392
Labeler:
Bayer Healthcare Pharmaceuticals Inc.
Vitrakvi 25 mg Oral Capsule
NDC: 71777-390
Labeler:
Loxo Oncology, Inc.
Vitrakvi 100 mg Oral Capsule
NDC: 71777-391
Labeler:
Loxo Oncology, Inc.
Vitrakvi 20 mg/ml Oral Solution
NDC: 71777-392
Labeler:
Loxo Oncology, Inc.